Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Teva Pharmaceutical Industries ADR
(NY:
TEVA
)
17.33
-0.49 (-2.75%)
Official Closing Price
Updated: 7:00 PM EST, Dec 6, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Teva Pharmaceutical Industries ADR
< Previous
1
2
3
4
5
6
7
8
Next >
Teva to Highlight Research in Respiratory Care at Upcoming 2021 American Thoracic Society International Conference
May 10, 2021
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva Announces New Environmental, Social and Governance (ESG) Strategy and Goals in 2020 Report
May 05, 2021
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva Announces Launch of its Generic Erythromycin Tablets USP, Used to Treat or Prevent a Variety of Bacterial Infections, in the United States
May 04, 2021
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva to Present New Long-Term AUSTEDO® (deutetrabenazine) Tablets Data at American Psychiatric Association Annual Meeting
May 03, 2021
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva Announces the Launch of the First Generic Version of Absorica® (isotretinoin) Capsules, for the Treatment of Severe Recalcitrant Nodular Acne in Patients 12 Years of Age and Older, in the United States
April 29, 2021
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva Reports First Quarter 2021 Financial Results
April 28, 2021
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva to Present New Analyses of AUSTEDO® (deutetrabenazine) Tablets and Assessment of Schizophrenia Clinical Outcomes at Upcoming 2021 American Psychiatric Association Annual Meeting
April 27, 2021
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva Announces Launch of its Generic Version of Canasa® (mesalamine) Suppositories To Treat Adults with Active Ulcerative Proctitis (ulcerative rectal colitis), in the United States
April 23, 2021
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
New Clinical and Real-World Data Evaluating Efficacy of AJOVY® (fremanezumab-vfrm) Injection and Reduction of Migraine Burden Presented at 2021 American Academy of Neurology Virtual Annual Meeting
April 19, 2021
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva to Present New Analyses of AJOVY® (fremanezumab-vfrm) Injection and AUSTEDO® (deutetrabenazine) Tablets at Upcoming 2021 American Academy of Neurology Virtual Annual Meeting, Highlighting Teva’s Ongoing Commitment to Neurology
April 15, 2021
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva Canada Announces New Autoinjector for AJOVY® for the Preventive Treatment of Migraine in Adults
April 08, 2021
From
Teva Pharmaceuticals Industries Ltd.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.